International Journal of Radiation Oncology * Biology * Physics
Volume 28, Issue 1 , Pages 7-16 , 1 January 1994

The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement

  • Steven A. Leibel, M.D.

      Affiliations

    • Corresponding Author InformationReprint requests to: Steven A. Leibel, M.D., Department of Radiation Oncology, Room 208H, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.
    • Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York, NY 10021, U.S.A.
    • ,
  • Zvi Fuks, M.D.

      Affiliations

    • Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York, NY 10021, U.S.A.
    • ,
  • Michael J. Zelefsky, M.D.

      Affiliations

    • Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York, NY 10021, U.S.A.
    • ,
  • Willet F. Whitmore Jr., M.D.

      Affiliations

    • Urology Service, Department of Surgery, New York, NY 10021, U.S.A.

,Accepted 1 June 1993.

References 

  1. American Joint Committee for Cancer Staging and End Results Reporting (AJCCS) . TNM staging of prostate cancer. In: 2nd edition. Manual for staging of cancer. Chicago: AJCCS; 1983;p. 119–124
  2. Anderson LL. Spacing nomograph for interstitial implant of interstitial implant of 125I seeds. Med. Phys. 1976;3:48–51
  3. Anderson LL, Aubery RF. Computerized dosimetry for 125I prostate implants. In:  Hilaris BS,  Batata MA editor. Brachytherapy oncology. New York: Memorial Sloan Kettering Cancer Center; 1983;p. 57–63
  4. Anscher MS, Prosnitz LR. Prognostic significance of nodal involvement in stage D1 prostate cancer treated with radiotherapy. Urology. 1992;39:39–43
  5. Aristizabal SA, Steinbronn D, Heusinkveld RS. External beam radiotherapy in cancer of the prostate: the University of Arizona experience. Radiother. Oncol. 1984;1:309–315
  6. Asbell SO, Krall JM, Pilepich MV, Baerwald H, Sause WT, Hanks GE, et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int. J. Radiat. Oncol. Biol. Phys. 1988;15:1307–1316
  7. Bagshaw MA. Potential for radiotherapy alone in prostatic cancer. Cancer. 1985;55:2079–2085
  8. Bagshaw MA. Radiotherapeutic treatment of prostatic carcinoma with pelvic node involvement. Urol. Clin. N. Amer. 1984;11:297–304
  9. Barzell W, Bean MA, Hilaris BS, Whitmore WF. Prostatic adenocarcinoma: Relationship of grade and local extent to the pattern of metastases. J. Urol. 1977;118:278–282
  10. Batata MA, Hilaris BS, Chu FCH, Whitmore WF, Song HS, Kim Y, et al. Radiation therapy in adenocarcinoma of the prostate with pelvic lymph node involvement on lymphadenectomy. Int. J. Radiat. Oncol. Biol. Phys. 1980;6:149–153
  11. Batata MA, Hilaris BS, Whitmore WF. Factors affecting tumor control. In:  Hilaris BS,  Batata MA editor. Brachytherapy oncology. New York: Memorial Sloan Kettering Cancer Center; 1983;p. 41–56
  12. Bishop JM. Molecular themes in oncogenesis. Cell. 1991;64:235–249
  13. Cordon-Cardo C, Fuks Z, Eisenbach L, Feldman M. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res. 1991;51:6372–6380
  14. Cox DR. Regression models and life tables. J. Roy. Statist. Soc. 1972;34:187–220Series B
  15. deKernion JB, Huang M-Y, Kaufman JJ, Smith RB. Results of treatment with stage D1 prostatic carcinoma. Urology. 1985;26:446–451
  16. Dewit L, Ang KK, avn der Scheuren E. Acute side effects and late complications after radiotherapy of localised carcinoma of the prostate. Cancer Treat. Rev. 1983;10:79–89
  17. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767
  18. Fowler JE, Whitmore WF. The incidence and extent of pelvic lymph node metastases in apparently localized prostatic cancer. Cancer. 1981;47:2941–2945
  19. Fuks Z, Leibel SA, Kutcher GE, Mohan R, Ling CC. Three dimensional conformal treatment: A new frontier in radiation therapy. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Important advances in oncology. Philadelphia, PA: Lippincott; 1991;p. 151–172
  20. Fuks Z, Leibel SA, Wallner KE, Begg CB, Fair WR, Anderson LL, et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: Long term results in patients treated with 125I implantation. Int. J. Radiat. Oncol. Biol. Phys. 1991;21:537–547
  21. Gervasi LA, Mata J, Easley JD, Wilbanks JH, Seale-Hawkins C, Carlton CE, et al. Prognostic significance of lymph nodal metastases in prostate cancer. J. Urol. 1989;142:332–336
  22. Golimbu M, Provet J, Al-Askari S, Morales P. Radical prostatectomy for stage D1 prostate cancer. Urology. 1987;30:427–435
  23. Grossman HB, Batata M, Hilaris B, Whitmore WF. 125I implantation for carcinoma of the prostate: Further follow-up of first 100 cases. Urology. 1982;20:591–598
  24. Hanks GE. External-beam radiation therapy for clinically localized prostate cancer: patterns of care studies in the United States. NCI Monogr. 1988;7:75–84
  25. Hanks GE, Krall JM, Pilepich MV, Asbell SO, Perez CA, Rubin P, et al. Comparison of pathologic and clinical evaluation of lymph nodes in prostate cancer: Implications of RTOG data for patient management and trial design andstratification. Int. J. Radiat. Oncol. Biol. Phys. 1992;23:293–298
  26. Harisiadis L, Veenema RJ, Senyszyn JJ, Pucher PJ, Tretter P, Romas NA, et al. Carcinoma of the prostate: Treat ment with external radiotherapy. Cancer. 1978;41:2131–2142
  27. Hilaris BS, Nori D, Anderson LL. Atlas of brachytherapy. In: New York: McMillan Publishing Co; 1988;p. 70–95
  28. Hill DR, Crews QE, Walsh PC. Prostate carcinoma: Radiation treatment of the primary and lymphatics. Cancer. 1974;34:156–160
  29. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49–53
  30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Amer. Statist. Assoc. 1958;53:457–816
  31. Kerbel RS. Towards an understanding of the molecular basis of the metastatic phenotype. Inv. Metast. 1989;9:329–337
  32. Kramer SA, Cline WA, Farnham R, Carson CC, Cox EB, Hinshaw W, et al. Prognosis of patients with stage D1 prostatic adenocarcinoma. J. Urol. 1981;125:817–819
  33. Lawton CA, Cox JD, Glisch C, Murray KJ, Byhardt RW, Wilson JF. Is long-term survival possible with external beam irradiation for stage D1 adenocarcinoma of the prostate?. Cancer. 1992;69:2761–2766
  34. Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Int. J. Radiat. Oncol. Biol. Phys. 1991;21:935–940
  35. Leibel, S. A.; Fuks, Z. The impact of local tumor control on the outcome in human cancer. In: Brady, L. W., Donner, M. D., Heilmann, H.-P., Heuck, H., eds. Medical radiology: Diagnostic imaging and radiation oncology. Berlin: Springer-Verlag; (In press).
  36. Leibel SA, Heimann R, Kutcher GJ, Zelefsky MJ, Burman CM, Melian E, et al. Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: Preliminary results of a phase I dose-escalation study. Int. J. Radiat. Oncol. Biol. Phys. 1994;28:55–65
  37. Leibel SA, Kutcher GJ, Mohan R, Harrison LB, Armstrong JG, Zelefsky MJ, et al. Three-dimensional conformal radiation therapy at the Memorial Sloan-Kettering Cancer Center. Sem. Radiat. Oncol. 1992;2:274–289
  38. Leibel SA, Ling CC, Kutcher GJ, Mohan R, Cordon-Cardo C, Fuks Z. The biological basis of conformal threedimensional radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1991;21:805–811
  39. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemo. Reports. 1966;50:163–170
  40. McGowan DG. The value of extended field radiation therapy in carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 1981;7:1333–1339
  41. Morales P, Golimbu M. The therapeutic role of pelvic lymphadenectomy in prostatic cancer. Urol. Clin. N. Amer. 1980;7:623–629
  42. Myers RP, Larson-Keller JJ, Bergstralh EJ, Zincke H, Oesterling JE, Lieber MM. Hormonal treatment at time of radical retropubic prostatectomy for stage D 1 pros tate cancer: Results of long-term followup. J. Urol. 1992;147:910–915
  43. Paulson DF. Carcinoma of the prostate: The therapeutic dilemma. Ann. Rev. Med. 1984;35:341–372
  44. Paulson DF. The prognostic role of lymphadenectomy in adenocarcinoma of the prostate. Urol. Clin. N. Amer. 1980;7:615–622
  45. Uro-Oncology Research GroupPaulson DF, Cline WA, Koefoot RB, Hinshaw W, Stephani S. Extended field radiation therapy versus delayed hormonal therapy in node positive prostatic adenocarcinoma. J. Urol. 1982;127:935–937
  46. Perez CA. Prostate. In:  Perez CA,  Brady LW editor. Principles and practice of radiation oncology. 2nd edition. Philadelphia: JB Lippincott; 1992;p. 25–26
  47. Pilepich MV. Radiation Therapy Oncology Group Studies in carcinoma of the prostate. N.C.I. Monogr. 1988;7:61–65
  48. Pilepich MV, Krall JM, Johnson RJ, Sause WT, Perez CA, Zinniger M, et al. Extended field (periaortic) irradiation in carcinoma of the prostate-analysis of RTOG 75-06. Int. J. Radiat. Oncol. Biol. Phys. 1986;12:345–351
  49. Ploysongsang SS, Aron BS, Shehata WM. Radiation therapy in prostate cancer: Whole pelvis with prostate boost or small field to prostate?. Urology. 1992;40:18–26
  50. Prout GR, Heaney JA, Griffin PP, Daly JJ, Shipley WU. Nodal involvement as a prognostic indicator in patients with prostatic carcinoma. J. Urol. 1980;124:226–231
  51. Rangala N, Cox JD, Byhardt RW, Wilson JF, Greenberg M, Lopes da Conceicao A. Local control and survival after external irradiation for adenocarcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 1982;8:1909–1914
  52. Rosen E, Cassady JR, Connolly J, Chaffey JT. Radiotherapy for prostate carcinoma: The JCRT experience (1968–1978). II. Factors related to tumor control and complications. Int. J. Radiat. Oncol. Biol. Phys. 1985;11:725–730
  53. Sagerman RH, Chu HC, King GA, Chung CT, Dalal PS. External beam radiotherapy for carcinoma of the prostate. Cancer. 1989;63:2468–2474
  54. Sause WW, Richards RS, Plenk H. Prostatic carcinoma: 5-year followup of patients with surgically staged disease undergoing extended field radiation. J. Urol. 1986;135:517519
  55. Schellhamer PF, Kuban DA, El-Mahdi AM. Local failure after definitive radiation or surgical therapy for carcinoma of the prostate and options for prevention and therapy. Urol. Clin. N. Amer. 1991;18:485–499
  56. Schmidt JD, McLaughlin AP, Saltzstein SL, Garcia-Reyes R. Risk factors for the development of distant metastases in patients undergoing pelvic lymphadenectomy for prostatic cancer. Am. J. Surg. 1982;133:617–619
  57. Shipley WA, Tepper JE, Prout GR, Verhey LJ, Mendiondo OA, Goitein M, et al. Proton radiation as boost therapy for localized prostatic carcinoma. J.A.M.A. 1979;1912–1915
  58. Smit WGJM, Helle PA, Van Putten WLJ, Wijnmaalen AJ, Seldenrath JJ, van der Werf-Messing BH. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int. J. Radiat. Oncol. Biol. Phys. 1990;18:23–29
  59. Smith JA, Haynes TH, Middleton RG. Impact of external irradiation on local symptoms and survival free of disease in patients with pelvic lymph node metastasis from adenocarcinoma of the prostate. J. Urol. 1984;131:705–707
  60. Smith JA, Middleton RG. Implications of volume of nodal metastasis in patients with adenocarcinoma of the prostate. J. Urol. 1985;133:617–619
  61. Smith JA, Seaman JP, Gleidman JB, Middleton RG. Pelvic lymph node metastasis from prostatic cancer: Influence of tumor grade and stage in 452 consecutive patients. J. Urol. 1983;130:290–292
  62. Sobel ME. Metastasis suppressor genes. JNCI. 1990;82:267–276
  63. Sogani PC. Pelvic lymphadenectomy: Techniques and complications. In:  Hilaris BS,  Batata MA editor. Brachytherapy oncology, 1983. New York: Memonal Sloan Kettering Cancer Center; 1983;p. 79–82
  64. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LP, et al. Evidence for a novel gene associated with low tumor metastatic potential. JNCI. 1988;89:200–203
  65. Steinberg GD, Epstein JI, Piantadosi S, Walsh PC. Management of Stage D 1 adenocarcinoma of the prostate: The Johns Hopkins experience 1974 to 1987. J. Urol. 1990;144:1425–1432
  66. Suit H, Urie M. Proton beams in radiation therapy. JNCI. 1992;84:155–164
  67. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, et al. Allelotype of colorectal carcinomas. Science. 1989;244:207–211
  68. Whitmore WF. The rationale and results of ablative surgery for prostatic cancer. Cancer. 1963;16:1119–1132
  69. Whitmore WF, Hilaris B, Grabstald H. Retropubic implantation of iodine 125 in the treatment of prostatic cancer. J. Urol. 1972;108:918–920
  70. Whitmore WF, Hilaris B, Grubstald H, Batata M. Implantation of 125I in prostatic cancer. Sur. Clin. N. Amer. 1974;54:887–895
  71. Yates F. The analyses of multiple classifications with unequal numbers in the different classes. J. Amer. Statist. Assoc. 1934;29:51–66
  72. Zagars GK, von Eschenbach AC, Johnson DE, Oswald MJ. Stage C adenocarcinoma of the prostate: An analysis of 551 patients treated with external beam radiation. Cancer. 1987;60:1489–1499
  73. Zincke H, Bergstralh EJ, Larson-Keller JJ, Farrow GM, Myers RP, Lieber MM, et al. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Cancer. 1992;70:311–323
  74. Zincke H, Utz DC. Observations on surgical management of carcinoma of prostate with limited nodal metastases. Urology. 1984;24:137–145
  75. Zincke H, Utz DC, Thulé PM, Taylor WF. Treatment options for patients with stage D1 (T0–3, N1–2, M0) adenocarcinoma of prostate. Urology. 1987;30:307–315

☆ Supported in part by grant CA 54749 from the National Cancer Institute, Department of Health and Human Services, Bethesda, MD.

PII: 0360-3016(94)90135-X

doi: 10.1016/0360-3016(94)90135-X

International Journal of Radiation Oncology * Biology * Physics
Volume 28, Issue 1 , Pages 7-16 , 1 January 1994

Article Tools